Kenya approves J&J, Pfizer Covid-19 vaccines as cases surge

Kenya approved the emergency use of Johnson & Johnson and Pfizer Inc. Covid-19 vaccines, said Fred Siyoi, chief executive officer of the Pharmacy and Poisons Board.

The East African nation expects to receive 13 million J&J doses starting this month. Kenya’s plan to inoculate its entire adult population of 26 million people by end of 2022 is reliant on J&J vaccines. About 10 million people will be vaccinated by the end of December, President Uhuru Kenyatta said last month. Kenya has so far inoculated less than 2.5% of its population of approximately 53 million people, using mostly doses from AstraZeneca.